|
- 现金
- 222032 元
- 精华
- 285
- 帖子
- 67620
- 注册时间
- 2001-11-10
- 最后登录
- 2023-5-7
|
1楼
发表于 2002-4-5 05:10
美国内华达州的 PhotoBioChem 公司公布, 公司的"光动力学消毒红血球发明"进入第一期临床试药/试验, 其动物实验效果很好. 公司今天又得赞助, 股票也涨.
大家都知道输血可以传染许多致命疾病, 艾滋病, 乙肝, 丙肝等. 许多抗原体都是附着在红血球上. 每年全球因为血液, 血液制品传染的疾病日益增多. 病毒是利用许多方法都不能消灭/排除掉的.
PhotoBioChem 的 "photodynamic red blood cell sterilization system, Sylsens(TM) 发明是将血液加入该公司的 Sylsens 溶液, 在一种特殊的光下照射15分钟, 之后用45分钟时间将 Sylsens 溶液分离出来, 该血液就象没有感染过一样! 这样就是在验血, 献血中漏掉的感染血也没关系, 因此输血造成的疾病将从此杜绝.
目前许多国家的红十字会, 血站都对此产品感兴趣. 科学家, 医务人员对于血液有关的产物要求是 "零危险度"!
******
附带:
Wednesday April 3, 2:00 am Eastern Time
Press Release
SOURCE: PhotoBioChem N.V.
PhotoBioChem N.V. has completed its first institutional financing of Euro 2,100,000 arranged by Oakes, Lyman & Co. Limited, in London
Johnson & Johnson Development Corporation was the lead investor
LEIDEN, Netherlands, April 3 /CNW/ - PhotoBioChem will immediately commence Phase I clinical trials for its photodynamic red blood cell sterilization system, Sylsens(TM). Sylsens is a pathogen inactivation system being developed to protect against infectious diseases resulting from the red blood cell transfusions.
Pre-clinical testing has established that bacteria, viruses and other pathogens in red blood cells can be rendered harmless through the use of the Sylsens system (1). Animal tests showed that Sylsens treated red blood cells were well tolerated and had recovery and survival rates comparable to untreated red blood cells.
The Sylsens system is fast, simple and safe. When red blood cells have been collected, Sylsens is added and the red blood cells are exposed to a specific light for about 15 minutes. After light exposure, the Sylsens compound is removed in a process taking approximately another 40-50 minutes after which the red blood cells are safe and ready for transfusion or storage.
While the blood supply is generally safe in a number of countries, new viruses and other pathogens emerge periodically such as AIDS. Over 25 million people are now thought to have been affected by the AIDS virus, over 300 million infected by Hepatitis B and Hepatitis C is the most common blood borne infection in the USA with over 3.9 million infected (2). The Sylsens system is expected to be effective against all of them even if they are undetectable through screening and testing.
Each year about 14 million units of whole blood are donated in the United States, 17 million units in Europe, and another 7 million units in Japan. The market for cellular blood products is over $3 billion. Pressure is growing to provide zero risk blood for transfusion.
Dr Richard S. Stokvis, CEO, of PhotoBioChem said: "The Sylsens system is designed to sterilize infected blood from donors who are either carrying a disease before it is detectable or carrying a disease that is not screened. Sylsens will also protect against new viruses and pathogens entering the blood supply. Blood banks throughout the world have shown interest in broad pathogen inactivation systems, such as Sylsens, to assist them in keeping the future blood supply safe."
-- About PhotoBioChem
-- PhotoBioChem N.V. is based at The University of Leiden, Netherlands.
-- 1 The Sylsens system has been successfully tested on all of the standard
-- protocols for pathogen elimination, red blood cell function and
-- toxicity. Currently there is no other viable technology on the market.
-- 2 Source: The Center for Disease Control and Prevention (www.cdc.gov).
For further information
Richard S. Stokvis, MD, Chief Executive Officer, PhotoBioChem N.V., +44 7884 187 792
[ 此消息由 liver411 在 2002-04-04.15:13:58 编辑过 ] |
|
